Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  regorafenib
Find trials that include:  Any drugs shown
Results 1-24 of 24 for your search:
Start Over
A Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Colon Cancer
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Tissue collection/Repository
Age: 18 and over
Trial IDs: NSABP C-13, NCI-2016-00467, 17808, NCT02664077
A Study to Investigate Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy Versus Regorafenib in Participants With Metastatic Colorectal Adenocarcinoma
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: GO30182, NCI-2016-01102, 2016-000202-11, NCT02788279
Guadecitabine and Irinotecan Hydrochloride or Regorafenib or TAS-102 Alone in Treating Patients with Previously Treated Metastatic Colorectal Cancer
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: NA_00085870, J1369, NCI-2013-02005, CIR00004735, CIR00013885, CIR0002117, j1369, NA_00085870, NCT01896856
Regorafenib in Treating Patients with Newly Diagnosed Metastatic Colorectal Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 13-211, NCI-2014-00002, NCT02023333
SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients With Refractory Liposarcoma, Osteogenic Sarcoma, and Ewing Sarcomas
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: SARC024, NCI-2014-02023, NCT02048371
Regorafenib in Treating Patients with Previously Treated, Metastatic, or Locally Advanced Angiosarcoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: NU 13S02, NCI-2013-02278, ONC-2013-129, STU00087654, NCT02048722
Regorafenib in Treating Patients With Advanced or Metastatic Biliary Tract Cancer Who Failed First-Line Chemotherapy
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: UPCI 13-100, NCI-2014-01117, NCT02053376
A Phase 2 Randomized, Open-Label Study of RRx-001 vs Regorafenib in Subjects With Metastatic Colorectal Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: RRx001-21-02, NCI-2014-00908, NCT02096354
Single Agent Regorafenib in Refractory Advanced Biliary Cancers
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MCC-17651, NCI-2014-00956, 14.02.0015, NCT02115542
Regorafenib in Treating Patients with Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction Who Have Completed Chemoradiation Therapy and Surgery
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: RU021212I, NCI-2015-01699, NCI-2014-01962, NCT02234180
Regorafenib in Treating Patients with Advanced or Metastatic Neuroendocrine Tumors
Status: Not yet active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 0S-14-3, NCI-2014-01996, HS-14-00583, NCT02259725
Regorafenib in Reducing Recurrence in Patients with Non-metastatic Rectal Cancer Who Have Completed Curative-Intent Treatment
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: I 246813, NCI-2014-02202, ONC-2013-036, NCT02287727
Vorinostat and Hydroxychloroquine or Regorafenib in Treating Patients with Refractory Metastatic Colorectal Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: CTMS 14-2015, NCI-2015-00203, 14-2015, 2015, HSC20150178H, NCI-2015-00175, NCT02316340
Lower or Standard Dose Regorafenib in Treating Patients with Refractory Metastatic Colorectal Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: RU021407I, NCI-2015-00011, Mod14-008756-03, NCT02368886
Regorafenib and Gemcitabine Hydrochloride as Second-Line Therapy in Treating Patients with Metastatic Pancreatic Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: CASE5214, NCI-2015-00146, NCT02383433
Study of Colorectal Cancer Patients (Stage IIIC) With Either Regorafenib or Standard of Care (No Treatment) After Adjuvant FOLFOX
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 13050, NCI-2015-01790, NCT02425683
Regorafenib in Metastatic Colorectal Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 70 and over
Trial IDs: 55555, NCI-2016-00641, NCT02466009
Regorafenib in Treating Patients with Metastatic Medullary Thyroid Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15-350, NCI-2016-00333, NCT02657551
Safety and Pharmacokinetics of Regorafenib and Cetuximab in Combination
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 16547, NCI-2013-02227, NCT01973868
A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: BBI608-246, NCI-2015-00892, NCT02024607
Regorafenib and Cetuximab in Treating Patients with Refractory or Relapsed Advanced Solid Tumor Malignancies
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2013-0833, NCI-2014-01307, NCT02095054
Regorafenib and Anti-ALK-1 Monoclonal Antibody PF-03446962 in Treating Patients with Refractory Metastatic Colorectal Cancer
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: Pro00051541, NCI-2014-01945, NCT02116894
Sunitinib Malate Alternating with Regorafenib in Treating Patients with Gastrointestinal Tumors That Are Metastatic or Cannot Be Removed by Surgery
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 14-149, NCI-2014-02033, ONC-2013-024, WI186553, NCT02164240
Regorafenib and Sildenafil Citrate in Treating Patients with Advanced Solid Tumors
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MCC-13-09812, NCI-2015-01101, NCT02466802
Start Over